[ATRS] Antares Pharma, Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.38 Change: 0.16 (7.21%)
Ext. hours: Change: 0 (0%)

chart ATRS

Refresh chart

Strongest Trends Summary For ATRS

ATRS is in the long-term up 42% above S&P in 2 years and up 132% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company?s injection products include OTREXUP, a pre-filled methotrexate syringe with Medi-Jet technology to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle. Its transdermal products comprise Gelnique3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company is also developing OTREXUP for the treatment poly-articular-course juvenile RA and psoriasis; Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency; Vibex auto injectors; and disposable

Fundamental Ratios
Shares Outstanding EPS-0.14 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 31.94% Sales Growth - Q/Q-0.64% P/E-20.71
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-56.49% ROE-94.3% ROI
Current Ratio1.97 Quick Ratio1.69 Long Term Debt/Equity Debt Ratio0.6
Gross Margin53.67% Operating Margin-111.47% Net Profit Margin-111.8% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-10 K Cash From Investing Activities180 K Cash From Operating Activities-10.66 M Gross Profit4.67 M
Net Profit-6.79 M Operating Profit-6.74 M Total Assets58.67 M Total Current Assets41.36 M
Total Current Liabilities21.05 M Total Debt Total Liabilities23.52 M Total Revenue8.35 M
Technical Data
High 52 week3.8 Low 52 week1.93 Last close3.01 Last change-1.95%
RSI61.11 Average true range0.14 Beta0.72 Volume2 M
Simple moving average 20 days4.37% Simple moving average 50 days-5.1% Simple moving average 200 days1.61%
Performance Data
Performance Week-4.14% Performance Month-0.33% Performance Quart-9.61% Performance Half11.9%
Performance Year35.59% Performance Year-to-date10.66% Volatility daily3.28% Volatility weekly7.34%
Volatility monthly15.04% Volatility yearly52.09% Relative Volume377.1% Average Volume1.15 M
New High2.16% New Low


2019-03-15 15:43:51 | Edited Transcript of ATRS earnings conference call or presentation 28-Feb-19 1:30pm GMT

2019-03-12 18:48:10 | Antares Pharma Inc ATRS Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

2019-03-06 07:00:00 | Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference

2019-03-04 07:00:00 | Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella

2019-02-28 12:31:49 | Antares Pharma Inc ATRS Q4 2018 Earnings Conference Call Transcript

2019-02-28 07:00:00 | Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

2019-02-27 07:00:00 | Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference

2019-02-25 17:00:00 | Antares Pharma to Report Fourth Quarter and Full Year 2018 Financial and Operating Results

2019-01-20 09:49:20 | Antares Pharma, Inc. NASDAQ:ATRS: Time For A Financial Health Check

2018-12-13 10:32:03 | What Kind Of Shareholder Appears On The Antares Pharma, Inc.’s NASDAQ:ATRS Shareholder Register?

2018-12-13 07:00:00 | Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors

2018-12-10 09:45:00 | ATRS: Xyosted & Epi Pen Available for Sale

2018-12-07 01:35:33 | Should You Buy NanoString Technologies Inc NSTG?

2018-12-05 17:09:43 | Is Noodles & Co NDLS A Good Stock To Buy?

2018-12-03 08:15:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Antares Pharma, Encana, PPG Industries, Cato, Cimarex Energy, and Ormat Technologies — New Research Emphasizes Economic Growth

2018-11-29 07:00:00 | Antares Pharma Announces the Commercial Availability of XYOSTED™ Testosterone Enanthate Injection — A New Treatment for Adult Men Diagnosed With Testosterone Deficiency

2018-11-28 08:39:01 | Teva TEVA Launches First Generic Version of Mylan's EpiPen

2018-11-27 13:47:28 | Teva's generic EpiPen hits the market in limited doses

2018-11-27 10:36:54 | Antares Pharma Partner Teva Announces Commercial Availability of Generic Epipen®

2018-11-26 10:45:00 | ATRS: Xyosted Launch Before Year End

2018-11-26 07:30:00 | Antares Pharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

2018-11-14 07:38:13 | Healthcare Value Capital, LLC Buys Antares Pharma Inc, Sells Novelion Therapeutics Inc

2018-11-12 20:06:13 | Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Antares Pharma, Inc. ATRS and Encourages ATRS Investors to Contact the Firm

2018-11-09 18:41:00 | Robbins Arroyo LLP: Antares Pharma, Inc. ATRS Misled Shareholders According to Class Action

2018-11-09 07:00:00 | Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting

2018-11-08 07:00:00 | Antares Pharma to Present at the Jefferies 2018 Global Healthcare Conference

2018-11-07 07:36:00 | Edited Transcript of ATRS earnings conference call or presentation 6-Nov-18 1:30pm GMT

2018-11-06 07:56:32 | Antares Pharma: 3Q Earnings Snapshot

2018-11-06 07:00:00 | Antares Pharma Reports Third Quarter 2018 Operating and Financial Results

2018-10-30 07:00:00 | Antares Pharma to Report Third Quarter 2018 Financial and Operating Results

2018-10-24 08:20:00 | Detailed Research: Economic Perspectives on Kohl's, Activision Blizzard, Amerco, Cree, Antares Pharma, and Uranium Energy — What Drives Growth in Today's Competitive Landscape

2018-10-22 14:23:15 | Antares Pharma Inc’s NASDAQ:ATRS Path To Profitability

2018-10-05 07:31:48 | Makena Auto Injector Is a Key Asset for Antares Pharma in 2018

2018-10-04 12:50:02 | Antares Pharma Is Expected to Report Positive EPS in 2019

2018-10-04 11:20:02 | Antares Pharma Could Report Solid Revenue Growth in Fiscal 2018

2018-10-04 09:46:46 | Here’s Why Antares Pharma Stock Rose on October 2

2018-10-02 15:43:28 | FDA approves injectable testosterone drug patients can administer by themselves at home

2018-10-02 12:52:00 | Here's Why Antares Pharma Jumped Higher Today

2018-10-01 07:53:42 | Antares Pharma's testosterone drug gets FDA approval

2018-10-01 07:00:00 | Antares Receives FDA Approval of Xyosted™ Testosterone Enanthate Injection for Testosterone Replacement Therapy in Adult Males

2018-09-25 07:00:00 | Antares Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference

2018-09-07 10:28:36 | Antares Pharma Inc’s NASDAQ:ATRS Earnings Dropped -9.2%, Did Its Industry Show Weakness Too?

2018-08-31 07:40:00 | Report: Developing Opportunities within Anthera Pharmaceuticals, NRG Energy, Antares Pharma, El Pollo Loco, Paychex, and Cinedigm — Future Expectations, Projections Moving into 2018

2018-08-30 07:00:00 | Antares Pharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

2018-08-27 09:15:00 | ATRS: Epinephrine Pen Ready to Go

2018-08-19 01:44:59 | Edited Transcript of ATRS earnings conference call or presentation 7-Aug-18 12:30pm GMT

2018-08-17 12:31:35 | Why the FDA's generic EpiPen approval is a big win for a N.J. company

2018-08-17 08:00:00 | Today’s Research Reports on Stocks to Watch: Antares Pharma and Adamis Pharmaceuticals

2018-08-16 16:54:50 | Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector